RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/16444283http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/16444283http://www.w3.org/2000/01/rdf-schema#comment"Insulin-like growth factor binding protein (IGFBP)-2 has mitogenic effects in normal and neoplastic cells. The purpose of this study is to examine the diagnostic and prognostic significance of elevated IGFBP-2 levels in children with AML after hematopoietic stem cell transplantation (HSCT) at relapse and continuous complete remission (CCR). In 27 children with AML (mean age 13.6+/-5.3 years; patients in remission n=15 with relapse n=12) serum parameters of IGFBP-2, IGFBP-3, IGF-I and IGF-II were analyzed up to 18 months after HSCT by RIA. AML-patients with evidence of relapse demonstrated a continuous increase of IGFBP-2 levels during the follow-up. At day 100 after HSCT, IGFBP-2 concentrations were significantly higher in patients with relapse than in children without relapse (7.4+/-4.0 standard deviation score (SDS) vs 3.9+/-1.7 SDS; P=0.01). Serum IGFBP-2 was identified as an independent factor for the prediction of relapse. Furthermore, the probability of relapse-free survival (RFS) in patients with IGFBP-2 >4.5 SDS at day 100 after HSCT was 31% compared to patients with IGFBP-2 <4.5 SDS was 72% (P=0.004). Patients with IGFBP-2 concentration up to 4.5 SDS more likely developed a relapse and had a poorer outcome. Identification of these patients allows a more individualized and aggressive adjuvant treatment and follow-up."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.org/dc/terms/identifier"doi:10.1038/sj.bmt.1705281"xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/author"Fuchs D."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/author"Gruhn B."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/author"Zintl F."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/author"Kauf E."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/author"Dawczynski K."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/author"Schlenvoigt D."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/date"2006"xsd:gYear
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/name"Bone Marrow Transplant"xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/pages"589-594"xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/title"Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML."xsd:string
http://purl.uniprot.org/citations/16444283http://purl.uniprot.org/core/volume"37"xsd:string
http://purl.uniprot.org/citations/16444283http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/16444283
http://purl.uniprot.org/citations/16444283http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/16444283
http://purl.uniprot.org/uniprot/#_C9JMY1-mappedCitation-16444283http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/16444283
http://purl.uniprot.org/uniprot/#_P18065-mappedCitation-16444283http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/16444283
http://purl.uniprot.org/uniprot/#_Q59FF1-mappedCitation-16444283http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/16444283
http://purl.uniprot.org/uniprot/C9JMY1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/16444283
http://purl.uniprot.org/uniprot/P18065http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/16444283
http://purl.uniprot.org/uniprot/Q59FF1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/16444283